Q1 Implantica

Interim Report January – March 2025

FINANCIAL SUMMARY

Figures within parentheses refer to the preceding year.

First quarter

- Net sales increased 25% to TEUR 745 (596).
- Adjusted gross margin amounted to 97% (92%).
- Operating loss (EBIT) decreased to TEUR 4,173 (7,087).
- Loss after tax decreased to TEUR 2,764 (3,472).
- Basic and diluted loss per Class A share amounted to EUR 0.04 (0.05).
- Cash and short-term investments as at the end of the period amounted to MEUR 60.3.

Significant Events

IN THE FIRST QUARTER OF 2025

- Received positive feedback from U.S. FDA on our Clinical Module 2 Premarket Approval (PMA) application. FDA accepted Module 1 containing the quality systems and manufacturing information for RefluxStop™, and this module is now considered closed
- Results from the largest real-world RefluxStop™ study published, involving 79 patients for up to 17 months follow-up in Germany showing median improvement in quality of life questionnaire, GERD-HRQL of 100%
- World-leading and largest hospital in Spain, La Paz University Hospital in Madrid, performed their first RefluxStop™ surgeries
- NHS Chelsea & Westminster Hospital hosted the first Gastrointestinal experts-focused RefluxStop™ educational meeting including 11 gastroenterologists

AFTER THE END OF THE PERIOD

- New study published in *Journal of Laparoendoscopic & Advanced Surgical Techniques* by Dr. Elshafei from St. Elisabethen Hospital in Frankfurt, Germany showing all preoperative heartburn, regurgitation and swallowing difficulties were completely resolved with RefluxStop™
- An additional three new hospitals performed their first RefluxStop™ surgeries in Spain, totaling 15 centers of excellence offering the RefluxStop™ procedure in Spain within two years from launch
- RCT kick-off meeting conducted with nine key opinion leaders in attendance, led by Prof. Schoppmann, the Principal Investigator of the randomized clinical trial of RefluxStop™ vs. Nissen fundoplication

Global expansion of RefluxStop™

In the first quarter of 2025, Implantica continues to make great strides in growing the RefluxStop™ user base in Europe and impressing the global reflux expert community with new clinical data showing outstanding treatment effect. The company achieved several critical milestones across global market expansion efforts, reimbursement process, clinical data development, and commercial dimensions that further solidify its position and bring it one step closer to its biggest launch, the U.S. market.


Dr. Peter Forsell, CEO Implantica

The upcoming U.S. Market Launch: FDA PMA

As reported before, the FDA has completed its review of RefluxStop's Premarket Approval (PMA) Module 2 submission, which included the most critical pieces of this submission in our opinion – clinical data, usability testing, and labeling. The agency's feedback was minor in nature and did not identify any material deficiencies, signaling a strong level of alignment according to our understanding. Implantica plans to submit the responses together with its final Module 3 submission in the near term. The FDA has now also confirmed that RefluxStop's production and packaging processes, which were submitted in Module 1, meet the required regulatory standards, positioning the company well for the upcoming pre-approval inspection of its manufacturing facilities. Collectively, this progress underscores that RefluxStop™ remains on track for obtaining an FDA approval and a grand US market launch immediately thereafter.

Strong RefluxStop™ adoption & patient satisfaction accelerating demand worldwide

RefluxStop™'s footprints continue to rapidly grow across Europe while echoing worldwide demand. During the reporting period, several prestigious hospitals began offering RefluxStop™, including Cromwell Hospital in the UK, and multiple high-volume centers in Spain such as Hospital Universitario La Paz in Madrid, Marques de Valdecilla in Cantabria, Central Asturias, and Vithas Valencia 9 de Octubre Hospital. The addition of these institutions not only enhances access to RefluxStop™ in new regions but also reflects rising demand from leading surgeons and continuously growing acceptance across public healthcare systems in key markets, which is crucial for establishing broader reimbursement. As of today, over 1,200 RefluxStop™ procedures have been successfully completed with many requests from patients and surgeons alike from all over the world to get access to this cutting-edge treatment option in their countries, underscoring continued adoption momentum and tremendous confidence from leading Reflux Surgeons. That said, turnover is not our top priority at the moment, we need 100% focus on quality as we are in the process of getting US approval soon, where all complications must be reported to the FDA. Many hospitals want to start operating with RefluxStop, but we are holding back. As hospitals are not yet paid by the healthcare systems, the number of surgeries that can be performed in each hospital is hampered. We are now step-by-step approaching a situation where RefluxStop can be incorporated into the normal reimbursed healthcare system, which will mean a dramatic increase in the number of surgeries adopted, however, at the earliest after our US approval.

Exceeding the highest & toughest expectations of experts through real-world evidence

Implantica continues to impress world-leading experts including its most critical audience by expanding the clinical body of evidence that surpasses everyone's expectations from real-world experience. A multitude of centers of excellence reinforce the robust outcomes of RefluxStop™.

A new study published in the *Journal of Laparoendoscopic & Advanced Surgical Techniques* by Dr. Elshafei, Chief of General and Visceral Surgery at St. Elisabethen Hospital in Frankfurt, Germany, reported complete resolution of key GERD symptoms—heartburn, regurgitation, and dysphagia—in all patients. These extraordinary results are particularly compelling given they closely mirror outcomes from the original CE mark study.

Continued validation from real-world clinical experience is evidenced by the results achieved in the largest real-world study on RefluxStop™ to date involving 79 patients, led by Dr. Lehmann from Klinikum Friedrichshafen, Germany and published in *Surgery Open Science,* an esteemed journal affiliated with *Surgery*. The study showed median improvement from baseline in GERD-HRQL quality of life

quesntionnaire score of 100% and mean improvement of 92.4%, an outstanding result.

Most of the real-world studies published by these independent RefluxStop™ surgeons include high-risk GERD patients with complex conditions that cannot be treated with previously existing treatments - and yet RefluxStop™ outcomes are exceptional across the board.

RefluxStop™ exceptional outcomes showcased at the world-leading medical congress, SAGES (Califonia, US)

The high level of engagement from the GI community was also evident at the 2025 SAGES Annual Meeting, where the five-year CE study results were presented by Professor Zehetner. A poster highlighting the outcomes of the first 100 patients treated was also shared, capturing considerable attention and discussion among surgical leaders. RefluxStop™'s presence at this most recognized US medical congress further elevates its profile in the US surgical community ahead of the planned regulatory approval.

RCT (RefluxStop™ vs. current surgical standard of care Nissen Fundoplication) Kick-off meeting

Implantica is launching the world's first and most ambitious superiority RCT against the surgical standard of care. We are partnering with some of the most renowned reflux centers and surgeons to bring this study to fruition as soon as possible. The immense interest to participate in this trial was self-evident from the global thought leaders who actively participated in the recent kickoff meeting for its randomized controlled trial (RCT), hosted at Implantica's operational headquarters in Switzerland. Nine key opinion leaders, including Principal Investigator Prof. Schoppmann gathered to finalize study design and execution plans. This pivotal trial, comparing RefluxStop™ to standard-of-care fundoplication, is designed to shape future clinical guidelines, accelerate reimbursement approvals and broad payer policy development in Europe and the U.S. The trial is expected to be enrolling patients soon after getting an updated Ethics approval in the respective countries.

Advancing interdisciplinary collaboration and therapy awareness to accelerate referrals

In January 2025, NHS Chelsea & Westminster Hospital hosted the first RefluxStop™-focused educational meeting for gastrointestinal experts. Eleven regional gastroenterologists joined surgeons from the hospital to review clinical data, discuss patient selection, and explore the device's unique mode of action, advancing cross-disciplinary collaboration and evidence-based education about RefluxStop™ procedure's outcomes.

Focus on strategic priorities in 2025

In short, Implantica is moving fast and making great progress with continued execution of its 2025 strategic top priorities, namely:

- finalize the last leg of the PMA process for the upcoming U.S. launch
- continue to expand European footprints and adoption
- further strengthen credibility with Payers by launching the best-in-class and most-ambitious RCTs against standard of care in the history of surgical GERD management
- Mobilize significant support from medical societies and expanding patient outreach and demand via physician awareness, strategic marketing & promotions, social media activities, patient education and therapy awareness campaigns

Implantica's progress represents a significant step forward for the hundreds of millions of patients suffering from reflux disease who urgently need a safe and lasting solution. Our clinical solution is designed for a superior clinical result, which now has been confirmed by the large number of published articles from many different centers of excellence and is the core of a successful launch worldwide.

Once again, we dedicate our progress and successes to our shareholders, business partners, employees, medical experts, and, most importantly, our patients who put their invaluable trust in Implantica.

Yours sincerely,
Dr. med. Peter Forsell, *Surgeon and Inventor*
CEO and Founder, Implantica

IMPLANTICA IN BRIEF

Implantica is a MedTech group committed to providing effective care for serious health conditions and improving patient quality of life by bringing advanced technology into the body. Simultaneously, Implantica aims to reduce overall costs and improve efficiency in the healthcare system.

The therapies Implantica develops are based on implants, which are inserted into the patient's body to replace bodily functions and/or treat diseases. Implantica has developed two platform technologies to be able to bring smart medical implants into the body.

Bringing advanced technology into the body requires enough power to activate a device inside the body long-term, which is the reason why a wireless energising platform has been developed. In addition, the Company has developed an eHealth platform for communicating with and reprogramming implants.

These platform technologies are covered by a multitude of patents and patent applications.

Implantica has developed a broad, patent protected, product pipeline, two-thirds of which is based on their two platform technologies.

Implantica's most progressed product, RefluxStop™, represents a potential paradigm shift in the treatment of GERD. Acid reflux has a significant impact on patient quality of life and can induce serious complications, including increased risk for oesophageal cancer.

GERD patients rely today, to a large extent, on PPIs – a drug therapy which calms symptoms of GERD. Ultimately, with PPI treatment reflux is not prevented and the risk for oesophageal cancer remains according to a report from Karolinska Institute. Alternative surgical procedures available today are plagued with complications, including compression of the food passageway and swallowing difficulties.

Top ten shareholders as of 10 April 2025

Name	Capital (%)
Peter Forsell	46.6%
Handelsbanken Fonder	8.9%
EFG Bank	6.9%
UBS	3.7%
UBP	2.7%
Avanza Pension	2.7%
SEB Life	2.2%
SIX SIS AG	1.6%
Nordea Liv	1.4%
Stephan Siegenthaler	1.3%

Financial performance in brief

Figures in parentheses within the following section refer to the corresponding period in the preceding year.

Net sales

During the first quarter, net sales amounted to EUR 745 thousand (596), corresponding to an increase of EUR 149 thousand or 25%. Implantica is currently exclusively marketing its lead product, RefluxStop™, to selected Key Opinion Leaders in Europe.

Cost of sales and gross margin

Cost of sales during the first quarter amounted to EUR 330 (356) thousand. Cost of sales considers two categories of costs. Firstly, indirect costs of straight-line amortisation of capitalised development costs relating to RefluxStop™. Secondly, Other cost of sales, which relates to direct costs for purchasing goods and services from the Group's outsourcing partners.

In the first quarter, adjusted gross margin[1], i.e., gross margin excluding amortization, amounted to 97% (92%).

Operating expenses and EBIT

In the first quarter, operating loss (EBIT) amounted to EUR 4,173 thousand (7,087), a decrease of EUR 2,914 thousand or 41%.

Research and development costs made up EUR 1,576 thousand (4,327), corresponding to a decrease of EUR 2,751 thousand or 64%. The year-on-year reduction of research and development costs is primarily explained by the substantial FDA submission preparation costs in the comparable period. Also, the costs for patent management and development of pipeline products decreased compared to the first quarter of 2024.

General and administrative costs amounted to EUR 3,012 thousand (3,000), an increase of EUR 12 thousand constituting an increase of less than 1%.

Financial income and expenses

Financial income amounted to EUR 1,445 thousand (3,637) during the first quarter thanks to foreign exchange gains and interest income. Financial expenses amounted to EUR 32 thousand (20) over the quarter explained by foreign exchange losses.

Income taxes

The Group reported a tax expense of EUR 4 thousand (2) in the first quarter. The tax expense for the quarter is mainly explained by changes in deferred tax assets.

Net earnings

The Group reported a net loss of EUR 2,764 thousand (3,472) for the first quarter, a decrease of EUR 708 thousand.

Equity and liabilities

As of 31 March 2025, the Group's equity amounted to EUR 96.6 million (117.0) and the equity ratio was 97%, compared to 96% at 31 March 2024.

As of 31 March 2025, the Group did not have any interest-bearing debt.

Cash flow and liquidity

During the first quarter, net cash outflow from operating activities amounted to EUR 4,525 thousand (6,465).

As of 31 March 2025, Implantica held cash and short-term investments of EUR 60.3 million. The short-term investments relate to six months term deposit agreements with an A+ rated Swiss bank.

Auditor's review

This report has not been reviewed by the company's auditors.

[1] Adjusted gross profit as a percentage of Net sales. Where Adjusted gross profit is defined as Net sales minus cost of sales, plus amortization of development costs.

Consolidated interim financial statements

Condensed consolidated statement of profit or loss

	Jan to Mar		Jan to Dec
in thousands of EUR	2025	2024	2024
Net Sales	745	596	1,936
Cost of sales			
Amortisation of capitalized development costs	(307)	(307)	(1,227)
Other cost of sales	(23)	(49)	(156)
Total cost of sales	(330)	(356)	(1,383)
Gross profit	415	240	553
Impairment of development costs	-	-	(1,669)
Research and development costs (Note 4)	(1,576)	(4,327)	(12,188)
General and administrative costs	(3,012)	(3,000)	(12,162)
Operating loss	(4,173)	(7,087)	(25,466)
Financial income	1,445	3,637	1,927
Financial expenses	(32)	(20)	(98)
Loss before income taxes	(2,760)	(3,470)	(23,637)
Income taxes	(4)	(2)	(49)
Loss for the period	(2,764)	(3,472)	(23,686)
Attributable to			
Owners of Implantica AG	(2,709)	(3,364)	(23,333)
Non-controlling interests	(55)	(108)	(353)
Loss for the period	(2,764)	(3,472)	(23,686)
Earnings per share (Note 5)			
Basic and diluted loss per share Class A (in EUR)	(0.04)	(0.05)	(0.34)
Basic and diluted loss per share Class B (in EUR)	(0.00)	(0.00)	(0.00)

Condensed consolidated statement of profit or loss and other comprehensive income

in thousands of EUR	Jan to Mar 2025	Jan to Mar 2024	Jan to Dec 2024
Loss for the period	(2,764)	(3,472)	(23,686)
Other comprehensive income			
Remeasurement of net defined benefit liability	(65)	(76)	46
Total items that will not be reclassified to profit or loss	*(65)*	*(76)*	*46*
Translation differences (Note 6)	(798)	(4,534)	(1,469)
Total items that may be reclassified subsequently to profit or loss	*(798)*	*(4,534)*	*(1,469)*
Other comprehensive income for the period, net of tax	(863)	(4,610)	(1,423)
Total comprehensive income for the period	(3,627)	(8,082)	(25,109)
Attributable to			
Owners of Implantica AG	(3,824)	(7,974)	**(24,756)**
Non-controlling interests	197	(108)	**(353)**
Total comprehensive income for the period	(3,627)	(8,082)	(25,109)

Condensed consolidated statement of financial position

in thousands of EUR	31 Mar 2025	31 Mar 2024	31 Dec 2024
ASSETS			
Current assets			
Cash and cash equivalents (Note 7)	25,753	80,082	64,552
Accounts receivable	820	453	589
Other current receivables	1,753	1,495	1,649
Inventories	206	214	226
Current financial assets (Note 7)	34,530	-	-
Total current assets	63,062	82,244	67,016
Non-current assets			
Property, plant and equipment	237	245	234
Right-of-use assets	493	757	571
Intangible assets (Note 4)	34,975	37,894	35,292
Deferred tax assets	966	986	966
Total non-current assets	36,671	39,882	37,063
Total assets	99,733	122,126	104,079
LIABILITIES AND EQUITY			
Current liabilities			
Trade payable	40	29	297
Financial liabilities	302	294	305
Financial liabilities due to ultimate main shareholder	1	1	1
Other current liabilities	2,208	3,681	2,694
Total current liabilities	2,551	4,005	3,297
Non-current liabilities			
Financial liabilities	214	486	290
Pension liability	404	614	334
Total non-current liabilities	618	1,100	624
Total liabilities	3,169	5,105	3,921
Equity			
Share capital (Note 6)	129,351	129,137	129,351
Capital reserves	370,548	370,548	370,548
Treasury share reserve (Note 6)	(66)	(2)	(71)
Translation differences (Note 6)	13,128	11,113	14,178
Retained earnings	(414,016)	(391,442)	(411,270)
Total equity attributable to owners of Implantica AG	98,945	119,354	102,736
Non-controlling interests	(2,381)	(2,333)	(2,578)
Total equity	96,564	117,021	100,158
Total liabilities and equity	99,733	122,126	104,079

Condensed consolidated statement of cash flows

in thousands of EUR	Jan to Mar 2025	Jan to Mar 2024	Jan to Dec 2024
Loss for the period	(2,764)	(3,472)	(23,686)
Adjustments for			
Depreciation, amortisation and impairment	408	410	3,300
Financial income	(1,445)	(3,637)	(1,927)
Financial expenses	32	20	98
Income taxes	4	2	49
Share-based compensation	33	57	221
Other financial result	(7)	(5)	(19)
Change in pension liabilities	10	(6)	72
Other non-cash items	(20)	(100)	(26)
Changes in net working capital			
Decrease / (increase) accounts receivable	(231)	(21)	(157)
Decrease / (increase) other current receivables	170	(506)	(660)
Decrease / (increase) inventories	20	97	85
(Decrease) / increase trade payable	(257)	29	297
(Decrease) / increase other current liabilities	(478)	667	(402)
Net cash outflow from operating activities	(4,525)	(6,465)	(22,755)
Cash flows from investing activities			
Purchase of property, plant and equipment	(25)	-	(36)
Investment in intangible assets (Note 4)	(8)	(471)	(406)
Investment in fixed term deposits (Note 7)	(34,220)	-	-
Interest received	10	107	787
Net cash inflow/(outflow) from investing activities	(34,243)	(364)	345
Cash flows from financing activities			
Payment of lease liabilities	(72)	(75)	(257)
Interest paid	(4)	(6)	(48)
Net cash outflow from financing activities	(76)	(81)	(305)
Net increase/(decrease) in cash and cash equivalents	(38,844)	(6,910)	(22,715)
Effect of exchange rate fluctuations on cash held	45	(930)	(655)
Cash and cash equivalents at beginning of period	64,552	87,922	87,922
Cash and cash equivalents at end of period	25,753	80,082	64,552

Condensed consolidated statement of changes in equity

in thousands of EUR	Jan to Mar 2025							
	Share capital	Capital reserves	Treasury share reserve	Translation differences	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 31 December 2024	129,351	370,548	(71)	14,178	(411,270)	102,736	(2,578)	100,158
Loss for the period	-	-	-	-	(2,709)	(2,709)	(55)	(2,764)
Other comprehensive income (net)	-	-	-	(1,050)	(65)	(1,115)	252	(863)
Total comprehensive income (net)	-	-	-	(1,050)	(2,774)	(3,824)	197	(3,627)
Share-based compensation	-	-	5	-	28	33	-	33
Total transactions with shareholders	-	-	5	-	28	33	-	33
Balance at 31 March 2025	129,351	370,548	(66)	13,128	(414,016)	98,945	(2,381)	96,564

in thousands of EUR	Jan to Mar 2024							
	Share capital	Capital reserves	Treasury share reserve	Translation differences	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 31 December 2023	129,137	370,548	(2)	15,647	(388,059)	127,271	(2,225)	125,046
Loss for the period attributable to owners of the Company	-	-	-	-	(3,364)	(3,364)	(108)	(3,472)
Other comprehensive income (net)	-	-	-	(4,534)	(76)	(4,610)	-	(4,610)
Total comprehensive income (net)	-	-	-	(4,534)	(3,440)	(7,974)	(108)	(8,082)
Share-based compensation	-	-	-	-	57	57	-	57
Total transactions with shareholders	-	-	-	-	57	57	-	57
Balance at 31 March 2024	129,137	370,548	(2)	11,113	(391,442)	119,354	(2,333)	117,021

Notes

NOTE 1 General information

Implantica AG (the 'Company') is domiciled at Aeulestrasse 45, 9490 Vaduz, Liechtenstein. These condensed consolidated interim financial statements ('interim financial statements') as at and for the three month ended 31 March 2025 comprise the Company and its subsidiaries (together referred to as the 'Group'). The Group is primarily involved in the research and distribution of medical implants. Implantica AG was admitted to trading on the Nasdaq First North Premier Growth Market in Stockholm in September 2020. Implantica AG is ultimately controlled by the Implantica Founder, Dr. Peter Forsell.

These interim financial statements were authorised for issue by the Company's Board of Directors on 8 May 2025. As of this date, no material events after the reporting date have occurred.

NOTE 2 Summary of significant accounting policies

Basis of preparation

These interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with the Group's consolidated financial statements as at and for the year ended 31 December 2024 ('last financial statements'). These interim financial statements do not include all of the information required for a complete set of financial statements prepared in accordance with IFRS Accounting Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last financial statements.

For the preparation of these financial statements the historical cost basis except for all those assets and liabilities measured at fair value has been applied. All amounts are presented in EUR, and are rounded to the nearest thousand of EUR with the consequence that the rounded amounts may not add to the rounded total in all cases. All ratios and variances are calculated using the underlying amounts rather than the rounded amounts.

Critical accounting estimates and judgements

In preparing these interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

NOTE 3 General accounting policies

The accounting policies applied in these interim financial statements are the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 December 2024.

There were no new standards or amendments to existing standards that have a material effect on the Group's interim financial statements.

Accounting standards issued but not yet effective

A number of new accounting standards and amendments to accounting standards are effective for annual periods beginning after 1 January 2025 and earlier application is permitted. The Group has not early adopted any of the forthcoming new or amended accounting standards in preparing these condensed consolidated interim financial statements.

NOTE 4 Intangible assets

	Jan to Mar	
in thousands of EUR	2025	2024
Net carrying amount at 1 January	35,292	38,163
Additions Jan to Mar	-	54
Amortization Jan to Mar	(316)	(318)
Translation differences	(1)	(5)
Net carrying amount at 31 Mar	34,975	37,894

For the first quarter research and development costs in the amount of EUR 1,576 thousand were recognised in profit or loss since the conditions for capitalisation as intangible assets for these costs are not met.

NOTE 5 Earnings per share

	Jan to Mar		Jan to Dec
in thousands of EUR	2025	2024	2024
Loss for the period attributable to owners of Implantica AG	(2,709)	(3,364)	(23,333)
Weighted average % of Class A share capital in total share capital	83.8%	83.8%	83.8%
Weighted average % of Class B share capital in total share capital	16.2%	16.2%	16.2%
Class A shares			
Loss for the period attributable to Class A shareholders	(2,270)	(2,818)	(19,549)
Weighted average number of outstanding Class A shares	58,179,203	58,110,245	58,111,738
Basic and diluted (loss) per share Class A (in EUR)	(0.04)	(0.05)	(0.34)
Class B shares			
Loss for the period attributable to Class B shareholders	(439)	(546)	(3,784)
Weighted average number of Class B shares	1,125,000,000	1,125,000,000	1,125,000,000
Basic and diluted (loss) per share Class B (in EUR)	(0.00)	(0.00)	(0.00)

Earnings per category of shares

Earnings per class of shares (Note 5) are calculated on the basis of the net loss attributable to the shareholders of Implantica AG based on their portion of the share capital and the average number of outstanding shares (i.e. excluding treasury shares).

Anti-dilutive effect of potential outstanding shares

The impact of share-based compensation arrangements was not considered in the diluted earnings per share calculation for Class A shares for the periods presented because due to the net loss for these periods their effect would have been anti-dilutive.

NOTE 6 Equity

Share capital

The fully paid in share capital of the Group amounts to CHF 138,923 thousand (EUR 129,351 thousand) and is divided into 58,211,537 registered shares with a nominal value of CHF 2.00 each (Class A) and 1,125,000,000 with a nominal value of CHF 0.02 each (Class B). As of 31 March 2025 a total number of 30,822 Class A shares are held by the Group (31 December 2024: 33,159).

During the period the Group delivered 2,337 Class A shares to employees as part of existing share-based payment commitments.

Translation differences

During the first quarter the EUR/CHF exchange rate decreased from 1.062 to 1.049. As a result, the group recognised a total loss of EUR 798 thousand in other comprehensive income related to the translation of financial statements of foreign operations and net investments in foreign operations.

NOTE 7 Cash and cash equivalents and financial assets

On 9 January 2025 the Group entered into a EUR 29,000 thousand and a SEK 60,000 thousand (EUR 5,220 thousand) six months term deposit agreements with an A+ rated Swiss bank. The interest rate is 2.65% for the EUR denominated and 2.13% for the SEK denominated fixed term deposit. As the duration is more than three months these instruments are classified as current financial assets.

Other

Telephone conference

Implantica will hold a teleconference on 9 May 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:

Webcast

If you wish to participate via webcast, please use the following link:

https://implantica.events.inderes.com/q1-report-2025

Dial-in

If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.

https://conference.inderes.com/teleconference/?id=5006347

Financial calendar

14 August 2025	Interim Report Q2 2025
31 October 2025	Interim Report Q3 2025

Listing

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company is traded under the ticker symbol IMP A SDB and ISIN code SE0014855029.

Disclaimer statement

Some statements herein are forward-looking, and the actual outcome could be materially different. In addition to the factors explicitly commented upon, the actual outcome could be materially affected by other factors, for example: the impact of undesired side effects related to existing or future products, failures in handling of the quality system, obstacles in obtaining CE and FDA approvals and re-certifications, products may fail to become subject to insurance and reimbursement policies and risk not gaining widespread acceptance, clinical trials may prove to be unsuccessful and the impact of competing products.

Contacts

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone: +41 (0)79 335 09 49
E-mail: nicole.pehrsson@implantica.com

Peter Forsell, CEO
E-mail: peter.forsell@implantica.com

Andreas Öhrnberg, CFO
E-mail: andreas.oehrnberg@implantica.com

Implantica AG
Aeulestrasse 45
9490 Vaduz
Liechtenstein

www.implantica.com